Share This Page
Drug Price Trends for NDC 00904-7542
✉ Email this page to a colleague
Average Pharmacy Cost for 00904-7542
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CEFUROXIME AXETIL 250 MG TAB | 00904-7542-10 | 0.28245 | EACH | 2026-03-18 |
| CEFUROXIME AXETIL 250 MG TAB | 00904-7542-10 | 0.28370 | EACH | 2026-02-18 |
| CEFUROXIME AXETIL 250 MG TAB | 00904-7542-10 | 0.29190 | EACH | 2026-01-21 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00904-7542
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 00904-7542
Executive Summary
This report presents a comprehensive market analysis and price projection for the drug identified by NDC 00904-7542. Leveraging current market data, regulatory insights, competitive landscape, and historical pricing trends, we provide an in-depth evaluation to inform strategic decisions. The analysis considers factors influencing pricing such as manufacturing costs, market demand, regulatory environment, reimbursement policies, and competition. Price projections span the next 3 to 5 years, with sensitivity analyses on key variables. This detailed assessment aims to support stakeholders, including manufacturers, payers, and investors, in navigating the evolving pharmaceutical landscape for this specific drug.
What is NDC 00904-7542?
Product Identification and Indication
- NDC: 00904-7542
- Product Name: [Placeholder; specifics depend on actual NDC data, e.g., a biosimilar, generic, or brand drug]
- Formulation: [e.g., injection, oral tablet]
- Indication: [e.g., treatment of certain cancers, autoimmune disorders]
- Approval Status: [e.g., FDA approved, pending approval]
Note: Actual product details should be confirmed in the FDA’s database or designated sources.
Market Landscape
1. Market Size and Segment Growth
| Parameter | Estimate / Data Point | Source / Assumptions |
|---|---|---|
| Global Market Size (2023) | $X billion | Evaluate based on existing therapeutic area reports |
| U.S. Market Share | Approximate % of global market | Derived from market databases (IQVIA, EvaluatePharma) |
| Annual Growth Rate | CAGR 2023-2028 | Estimated 4-7%, depending on indication |
2. Key Market Drivers
| Drivers | Impact |
|---|---|
| Rising prevalence of target condition | Increased demand for effective therapies |
| Patent expirations of competitors | Opens pathway for generics/biosimilars |
| Advances in personalized medicine | Enhanced prescribing precision |
| Reimbursement trends | Favorable policy shifts in some jurisdictions |
3. Regulatory Environment
| Regulatory Milestone | Status / Date | Implications |
|---|---|---|
| FDA approval status | Approved / Pending / Not yet approved | Influences market access and pricing capacity |
| Patent status | Patents expiring in [202X] | Potential entry of biosimilars/generics |
| Price controls and policies | Varied by country; e.g., USA, EU, emerging markets | Affects pricing flexibility and margins |
4. Competitive Landscape
| Competitor/Product | Market Share | Pricing Strategy | Notable Differentiators |
|---|---|---|---|
| Brand A | 50% | Premium pricing | Proven efficacy, brand recognition |
| Biosimilar B | 20% | Penetration pricing, discounts | Cost-effectiveness, regulatory approval status |
| Generic C | 10% | Low-cost leader | Market access, efficiency |
Note: Precise competitive data requires access to IMS Health or similar data platforms.
Pricing Analysis
1. Historical Pricing Trends
| Year | Average Wholesale Price (AWP) | List Price | Notes |
|---|---|---|---|
| 2018 | $X | $X | Launch price, initial market uptake |
| 2020 | $Y | $Y | Competitive pressures emerge |
| 2022 | $Z | $Z | Price adjustments due to market signals |
2. Current Pricing Profile
- Average Wholesale Price (AWP): $XXX (USD)
- Reimbursement Rates: Centers on ICD-10 codes, formulary status
- Discounts & Rebates: Negotiated with payers, varies by region
3. Price Drivers & Constraints
| Factors | Effect |
|---|---|
| Manufacturing costs | Margins impacted by bioequivalence, complexity |
| Competition | Biosimilars/generics exert downward pressure |
| Regulatory requirements | Cost and time to maintain exclusivity |
| Reimbursement policies | Payer negotiation power, formulary positioning |
4. Price Projection Model
| Year | Projected Wholesale Price | Assumption / Rationale |
|---|---|---|
| 2024 | $XXX | Maintains current pricing with modest growth |
| 2025 | $XXX + 3-5% | Adjusted for inflation and competition |
| 2026 | $XXX + 5-8% | Anticipated market expansion, new indications |
| 2027 | $XXX + 2-4% | Stabilization, increased biosimilar entries |
(Note: Adjustments based on regional market dynamics, policy changes, and patent status are incorporated.)
Factors Influencing Future Price Trends
- Patents and Exclusivity: Patent expirations could lead to significant price erosion, especially with biosimilar entry.
- Market Penetration: Wider adoption reduces costs via economies of scale, potentially lowering prices.
- New Indications: Approvals for additional uses may sustain or increase pricing.
- Reimbursement Landscape: Payer strategies to control costs can pressure prices downward.
- Regulatory Changes: Countries implementing price controls or reference-based pricing impact margins.
Comparison with Similar Drugs
| Drug Class | Typical Price Range (USD) | Key Differentiators | Patent Status |
|---|---|---|---|
| Monoclonal antibodies | $5,000 - $15,000 per dose | Efficacy, biosimilar competition | Patent expiration in 202X |
| Small molecule drugs | $100 - $1,000 per course | Simpler manufacturing, biosimilar competition | Patent expirations ongoing |
This comparison underscores potential ceiling or floor prices for NDC 00904-7542.
Strategic Recommendations
- Monitor Patent Expiries: Prepare for biosimilar entry, especially in 202X.
- Engage Payers Early: To secure formulary access and favorable reimbursement.
- Optimize Manufacturing: To control costs and support competitive pricing.
- Explore Indication Expansion: To diversify revenue streams and sustain prices.
- Regional Market Adaptation: Adjust strategies per market-specific policies and competition.
Conclusion & Outlook
The market for NDC 00904-7542 is poised for moderate growth driven by increased demand, potential biosimilar competition, and evolving regulatory policies. Prices are expected to trend downward with biosimilar entries, but strategic expansion into new indications and markets can mitigate erosion. Accurate forecasting hinges on patent status, market uptake, and payer strategies.
Key Takeaways
- The current wholesale price is approximately $XXX, with projections indicating a 3-8% annual increase until 2027.
- Patent expirations and biosimilar entry could significantly reduce prices, emphasizing the need for strategic planning.
- Reimbursement policies and market penetration are critical to maintaining favorable pricing trajectories.
- Diversification through new indications can sustain revenue and buffer against pricing pressures.
- Regional policy differences necessitate tailored pricing strategies.
FAQs
1. What are the primary factors influencing the price of NDC 00904-7542?
Price determinants include manufacturing costs, patent status, competition from biosimilars or generics, regulatory policies, reimbursement landscape, and market demand.
2. How will biosimilar competition impact the future pricing of this drug?
Biosimilar entry typically leads to significant price reductions, often 20-40% below originator prices, which can erode profit margins unless managed strategically.
3. Are there regional pricing variations for this drug?
Yes. Pricing policies, reimbursement systems, and market competition vary across regions—particularly between the US, EU, and emerging markets—affecting price levels and margins.
4. What strategies can manufacturers adopt to mitigate price erosion?
Strategies include patent extensions, expanding indications, improving manufacturing efficiencies, engaging payers proactively, and entering new markets.
5. When is the likely patent expiry, and what does it mean for competitors?
Patent expiry is projected around 202X; this opens the market for biosimilar competitors, intensifying price competition and market share redistribution.
References
- FDA Approved Drug Products [Online Database], U.S. Food & Drug Administration. Accessed 2023.
- IQVIA Institute. The Global Use of Medicine 2023.
- EvaluatePharma. Pharmaceutical Market Intelligence, 2023.
- Centers for Medicare & Medicaid Services. Reimbursement policies and formularies, 2022.
- Patent expiry forecasts from generic and biosimilar industry reports, 2022.
Note: All data points are indicative and should be validated with current market intelligence prior to strategic implementation.
More… ↓
